文献速递临床生化临床免疫

生长分化因子15作为心血管疾病生物标志物

Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.
PubMed 文献 · Clin Chem · 2016-10-25

生长分化因子15(GDF-15)在炎症、氧化应激、缺氧等刺激下表达分泌,心血管疾病是其产生的主要驱动因素。在社区人群中,GDF-15浓度升高与心血管疾病、慢性肾脏病和癌症风险增加独立相关;低浓度与长寿密切相关。GDF-15是冠心病患者全因死亡和心血管事件的独立标志物,可能有助于非ST段抬高急性冠脉综合征患者的早期血运重建选择,并与房颤、心衰的死亡和非致命事件独立相关。

要点

  • GDF-15浓度升高独立于传统风险因素预测社区人群心血管疾病、慢性肾脏病和癌症风险。
  • GDF-15是冠心病患者全因死亡和心血管事件的独立标志物,可能辅助非ST段抬高急性冠脉综合征的风险分层。
  • GDF-15与房颤、心衰的死亡和非致命事件独立相关,并反映心衰慢性疾病负担和急性扰动。

核心结论

  • GDF-15反映了心血管疾病发生、发展和预后的不同方面,这些方面未被临床风险预测因素和其他生物标志物所代表。
  • GDF-15指导管理决策和发现新治疗靶点的效用有待进一步探索。

研究设计与样本

  • 综述性文章,总结了GDF-15作为心血管疾病生物标志物的相关研究证据。

主要发现

  • 在社区居住个体中,较高浓度的GDF-15与心血管疾病、慢性肾脏病和癌症风险增加相关,独立于传统心血管风险因素、肾功能和其他生物标志物(C反应蛋白、B型利钠肽、心肌肌钙蛋白)。
  • 低浓度的GDF-15与长寿密切相关。
  • GDF-15是冠心病患者全因死亡和心血管事件的独立标志物。
  • GDF-15可能有助于选择非ST段抬高急性冠脉综合征患者进行早期血运重建和更强化药物治疗。
  • GDF-15与房颤和射血分数保留或降低的心衰患者的死亡和非致命事件独立相关。

临床怎么用

  • GDF-15可作为心血管疾病风险分层的辅助生物标志物,尤其适用于传统风险因素无法充分解释风险的情况。
  • 在非ST段抬高急性冠脉综合征患者中,GDF-15可能辅助早期血运重建决策。
  • GDF-15可用于心衰和房颤患者的预后评估,并可能辅助抗血栓治疗患者的出血风险决策支持。

局限性

  • GDF-15指导管理决策和发现新治疗靶点的效用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growth differentiation factor 15 (GDF-15) is expressed and secreted in response to inflammation, oxidative stress, hypoxia, telomere erosion, and oncogene activation. Cardiovascular (CV) disease is a major driver of GDF-15 production. GDF-15 has favorable preanalytic characteristics and can be measured in serum and plasma by immunoassay. CONTENT: In community-dwelling individuals higher concentrations of GDF-15 are associated with increased risks of developing CV disease, chronic kidney disease, and cancer, independent of traditional CV risk factors, renal function, and other biomarkers (C-reactive protein, B-type natriuretic peptide, cardiac troponin). Low concentrations of GDF-15 are closely associated with longevity. GDF-15 is as an independent marker of all-cause mortality and CV events in patients with coronary artery disease, and may help select patients with non-ST-elevation acute coronary syndrome for early revascularization and more intensive medical therapies. GDF-15 is independently associated with mortality and nonfatal events in atrial fibrillation and heart failure (HF) with preserved or reduced ejection fraction. GDF-15 reflects chronic disease burden and acute perturbations in HF and responds to improvements in hemodynamic status. GDF-15 is independently associated with major bleeding in patients receiving antithrombotic therapies and has been included in a new bleeding risk score, which may become useful for decision support. SUMMARY: GDF-15 captures distinct aspects of CV disease development, progression, and prognosis, which are not represented by clinical risk predictors and other biomarkers. The usefulness of GDF-15 to guide management decisions and discover new treatment targets should be further explored.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Wollert KC, Kempf T, Wallentin L, et al. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2016. PMID: 28062617. doi:10.1373/clinchem.2016.255174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。